HC Wainwright Raises ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $53.00

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) had its target price raised by HC Wainwright from $50.00 to $53.00 in a research report released on Monday morning, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, Guggenheim began coverage on shares of ANI Pharmaceuticals in a report on Tuesday, February 28th. They issued a buy rating and a $55.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $52.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $41.01 on Monday. The firm’s 50 day moving average price is $43.06 and its 200-day moving average price is $39.10. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.40 and a current ratio of 3.46. ANI Pharmaceuticals has a one year low of $22.31 and a one year high of $45.99. The firm has a market cap of $716.44 million, a P/E ratio of -13.49 and a beta of 1.06.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Martingale Asset Management L P lifted its holdings in ANI Pharmaceuticals by 1.9% during the 4th quarter. Martingale Asset Management L P now owns 16,221 shares of the specialty pharmaceutical company’s stock worth $653,000 after buying an additional 295 shares in the last quarter. Texas Permanent School Fund lifted its holdings in ANI Pharmaceuticals by 3.9% during the 2nd quarter. Texas Permanent School Fund now owns 9,371 shares of the specialty pharmaceutical company’s stock worth $278,000 after buying an additional 350 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of ANI Pharmaceuticals by 20.0% in the 2nd quarter. Mutual of America Capital Management LLC now owns 2,200 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 367 shares in the last quarter. American International Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 7.2% in the 2nd quarter. American International Group Inc. now owns 6,866 shares of the specialty pharmaceutical company’s stock valued at $204,000 after purchasing an additional 461 shares in the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in shares of ANI Pharmaceuticals by 2.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 24,249 shares of the specialty pharmaceutical company’s stock valued at $719,000 after purchasing an additional 499 shares in the last quarter. 67.89% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

(Get Rating)

ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.